ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO444

Polycystic Kidney Disease Is Significantly Associated with Alzheimer Dementia RiskPropensity Score Matched Analysis of a Nationwide, Population-Base Cohort

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 306 CKD: Cognitive Dysfunction, Depression, Quality of Life


  • Yu, Tung-Min, Taichung Veterans General Hospital, Taichung ---, Taiwan
  • Chuang, Ya-Wen, Taichung Veterans General Hospital, Taichung ---, Taiwan
  • Moriishi, Misaki, Tsuchiya General Hospital, Hiroshima, Hiroshima, Japan
  • Tsuchiya, Shinichiro, Tsuchiya General Hospital, Hiroshima, Hiroshima, Japan

Data on the risk of neurodegenerative diseases, including Alzheimer disease and Parkinson disease, in patients with polycystic kidney disease (PKD) are lacking.


A total of 4229 patients who were aged ≥20 years and had received a diagnosis of PKD were included in the PKD cohort. For each PKD case identified, 1 participant aged ≥20 years without a history of PKD, dementia, or PD was selected from the comparison cohort. For each patient with PKD, the corresponding controls were selected 1:1 on the basis of the nearest propensity score calculated using logistic regression.


The incidence density rates of dementia were 4.31 and 2.50 per 1000 person-years in the PKD and control cohorts, respectively. A 2.04-fold higher risk of dementia was observed in patients with PKD than in controls (adjusted hazard ratio [aHR] = 2.04; 95% confidence interval [CI] = 1.46–2.85). Regarding the risk of different dementia subtypes including AD and vascular dementia (VD), the aHR for AD and pre-senile dementia was 2.71 (95% CI = 1.08–6.75) and that for VD was 0.90 (95% CI = 0.43–1.87) in patients with PKD compared with controls, after adjustment for age, sex, and comorbidities. Compared with controls, the risk of PD increased by 1.78-fold (95% CI = 1.14–2.79) in patients with PKD.


In clinical practice, health care professions should be aware of the risk of these neurodegenerative diseases in patients with PKD.